title: A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg----214Trp mutation.
abstract: We describe a new variant of Glanzmann's thrombasthenia (variant Strasbourg I). The patient (M.S.) showed an absence of platelet aggregation to ADP, thrombin, and collagen, and a decreased clot retraction. Platelet fibrinogen was approximately 20% of normal levels. ADP-stimulated platelets bound markedly reduced amounts of soluble fibrinogen and platelet adhesion to surface-bound fibrinogen was defective. Normal to subnormal amounts of glycoprotein (GP) IIb-IIIa (alpha IIb beta 3) complexes, the platelet fibrinogen receptor, were revealed by SDS-PAGE, crossed immunoelectrophoresis, and antibody binding. However, the complexes were unusually sensitive to dissociation with EDTA at room temperature. Furthermore, flow cytometry showed that the platelets failed to bind the activation-dependent monoclonal antibody, PAC-1, after stimulation. In contrast, an RGDS-containing peptide induced significant binding of the anti-ligand-induced binding site antibody, D3GP3, suggesting the presence of a functional RGD binding domain on the patient's GPIIb-IIIa complex. Sequence analysis was performed after polymerase chain reaction amplification of selected patient's GPIIIa exons, and of the patient's platelet GPIIb and GPIIIa mRNAs. A point mutation (C to T) was localized in exon D (iv) of GPIIIa that resulted in an 214Arg to 214Trp amino acid substitution. The defect has been inherited from the parents who are heterozygous for the same mutation. This substitution points to an essential amino acid in a region of GPIIIa involved in the binding of fibrinogen and influencing the Ca(2+)-dependent stability of the GPIIb-IIIa complex.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale Unité 311, Centre Régional de Transfusion Sanguine, Strasbourg, France.
authors.forename: F
authors.initials: F
authors.lastname: Lanza
authors.forename: A
authors.initials: A
authors.lastname: Stierlé
authors.forename: D
authors.initials: D
authors.lastname: Fournier
authors.forename: M
authors.initials: M
authors.lastname: Morales
authors.forename: G
authors.initials: G
authors.lastname: André
authors.forename: A T
authors.initials: AT
authors.lastname: Nurden
authors.forename: J P
authors.initials: JP
authors.lastname: Cazenave
mesh_terms: D000328:Adult; D000595:Amino Acid Sequence; D001483:Base Sequence; D001792:Blood Platelets / Q000378:metabolism*; D004247:DNA; D004252:DNA Mutational Analysis; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D039421:Integrin alpha2; D008562:Membrane Glycoproteins / Q000235:genetics*; D008969:Molecular Sequence Data; D009154:Mutation; D010974:Platelet Aggregation; D016133:Polymerase Chain Reaction; D013915:Thrombasthenia / Q000235:genetics* / Q000378:metabolism
chemical_list: C056564:ITGA2B protein, human; D039421:Integrin alpha2; D008562:Membrane Glycoproteins; C040580:glycoprotein GP III; D005340:Fibrinogen; D004247:DNA